Physician profile
Heather Smith
NPI 1376384818
$2,206.44
in general payments reported to CMS, 2019-2025
15 companies · $895 in 2025
The $895 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,312 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206 · Travel and Lodging: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.64 |
| Travel and Lodging | $1,000.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $1,000.80 | 2024 | |
| Abbvie INC. | $473.19 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $161.45 | 2025 | Rexulti, Abilify Asimtufii |
| Novocure INC. | $101.20 | 2024 | |
| Lundbeck LLC | $79.64 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $66.28 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $55.14 | 2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $51.02 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.22 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $41.54 | 2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $32.60 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $31.20 | 2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.12 | 2025 | Abilify Maintena |
| Bausch Health US, LLC | $19.65 | 2025 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $18.39 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.